| Aug 8 |
Coherus BioSciences GAAP EPS of -$0.11 beats by $0.09, revenue of $65M beats by $8.58M
|
| Aug 8 |
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Aug 7 |
Coherus BioSciences Q2 2024 Earnings Preview
|
| Aug 1 |
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
|
| Jul 2 |
Coherus out licenses Canadian rights to cancer drug Loqtorzi
|
| Jun 28 |
PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
|
| Jun 27 |
Coherus to divest biosimilar against AbbVie’s Humira for $40M
|
| Jun 27 |
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
|
| Jun 5 |
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
|
| May 31 |
Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway
|
